Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00867971

Enrollment

100

Registered

2009-03-24

Start date

2009-02-28

Completion date

2010-10-31

Last updated

2009-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Growth Hormone Treatment

Brief summary

Recombinant growth hormone is a common therapy in the pediatric population. A number of associated side effects have been described. Several years ago, a case report was published concerning a child that was treated with RGH and developed acute glaucoma. To date no study has evaluated the connection.

Interventions

OTHERMeasuring intraoccular pressure

Measurement of intraoccular pressure by tonometry

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

6 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Age 6-18 years * treatment with recombinant growth hormone

Exclusion criteria

* Underlying Chronic diseases * Family history of eye diseases * elevated occular pressure prior to starting treatment

Design outcomes

Primary

Measure	Time frame
Intraoccular pressure in children treated with RGH	2 years

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026